Vaccine Code Set Update Publication Date: March 20, 2024
The individual filenames included in this distribution contain the publication date (20240320)
Release Notes:This release includes updates to all vaccine codes and maps but does not include Vaccine Information Statements (VIS) related code updates.
General Note Regarding this Release: Codes with “Last Update” dates after January 30, 2023, and before March 16, 2024, reflect the changes and additions in this release. This release includes the following code set updates:
- New Unspecified Anthrax Vaccine CVX Code 319 Added
- CPT To CVX Maps for Yellow Fever and DTaP Vaccines Updated
- New NDCs Added and Associated to Existing CVX, MVX, and Product
- New Southern Hemisphere Influenza Vaccines for 2024 Season
- Other New NDCs
- NDC Pairs Retired
- Other Updates to Existing NDC Records
- Other NDC Updates not Included in the Published Code Fields
Vaccine Code Set Updates – Details
- New Unspecified Anthrax Vaccine CVX Code 319 Added
A new unspecified CVX code has been added to allow recording of a historic vaccine administration where the formulation administered is not known. This has become necessary with the introduction of a second anthrax vaccine, CYFENDUS, which has a separate CVX code and formulation from the original Biothrax formulation (CVX code 24).
- All anthrax CVX codes are associated with vaccine group ANTHRAX. The following CVX code has been added. Note that unspecified codes are added with a status of “Inactive”.
| CVX Code | CVX Long Description | CVX Short Description | CVX Status |
|---|
319
(NEW)
| Anthrax vaccine, unspecified
| Anthrax vaccine, unspecified
| Inactive
|
|---|
- CPT to CVX Maps for Yellow Fever and DTaP Vaccines Updated
| Change Description | CPT Code | CPT Long Description | CVX Code | CVX Long Description | CVX Note |
|---|
| Yellow Fever CPT to CVX Map Updates |
|---|
| Removed CPT to CVX map: CPT codes should not be mapped to unspecified codes.
| 90717
| Yellow fever vaccine, live, for subcutaneous use
| 184
| Yellow fever vaccine, unspecified formulation
| none
|
|---|
| Added CPT to CVX map and updated CVX code description fields: Add reference to "live". CVX code 37 is associated to the YF-VAX product NDCs.
| 90717
| Yellow fever vaccine, live, for subcutaneous use
| 37
| yellow fever vaccine live
| This is the YF vaccine that has been available in the US for years. It is stabilized with sorbitol and gelatin.
|
|---|
| Added CPT to CVX map and updated CVX code description and note fields: Add reference to use of this vaccine for a vaccine shortage. CVX code 183 is associated to the Stamaril product NDCs.
| 90717
| Yellow fever vaccine, live, for subcutaneous use
| 183
| Yellow fever vaccine live - alternative formulation for vaccine shortage
| This CVX is associated to an FDA unapproved drug to be used when there is a drug shortage. Stabilized with sorbitol and lactose and has been used outside the US for some time.
|
|---|
| DTaP CPT to CVX Map Updates |
|---|
| Existing CPT to CVX map not changed: CVX code 20 is associated to Infantrix NDCs.
| 90700
| Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than 7 years, for intramuscular use
| 20
| diphtheria, tetanus toxoids and acellular pertussis vaccine
| none
|
|---|
| Added CPT to CVX map:CVX code 106 is associated to DAPTACEL NDCs.
| 90700
| Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than 7 years, for intramuscular use
| 106
| diphtheria, tetanus toxoids and acellular pertussis vaccine, 5 pertussis antigens
| none
|
|---|
- New NDCs Added and Associated to Existing CVX, MVX, and Product
- New Southern Hemisphere Influenza Vaccines for 2024 Season
The following three new vaccines have been added. Seasonal influenza vaccine tables have been updated on CDC’s website: Fall Season Respiratory Vaccine Codes | CDC
| CVX Code | CVX Short Description | Sale Proprietary Name | Sale Labeler | MVX
Code | Sale NDC11 | Use NDC11 | Presentation |
|---|
| 201
| influenza, Southern Hemisphere, preservative free
| FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE
| Sanofi Pasteur Inc.
| PMC
| 49281-0324-50
| 49281-0324-88
| SYRINGE, 0.5 mL
|
|---|
| 202
| influenza, Southern Hemisphere, quadrivalent, with preservative
| FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE
| Sanofi Pasteur Inc.
| PMC
| 49281-0398-15
| 49281-0398-78
| VIAL, MULTI-DOSE, 5 mL
|
|---|
| 231
| influenza, Southern Hemisphere, high-dose, quadrivalent
| FLUZONE High-Dose Quadrivalent Southern Hemisphere
| Sanofi Pasteur Inc.
| PMC
| 49281-0933-50
| 49281-0933-88
| SYRINGE, .7 mL
|
|---|
- Other New NDCs Added and Associated to Existing CVX, MVX, and Product
New relabeled NDCs for Merck’s PNEUMOVAX 23 product have been added by relabeler A-S Medication Solutions. The MVX code is assigned to the manufacturer.
| Sale Proprietary Name | Sale Labeler | Sale NDC11 | Use NDC11 | CVX Code | CVX Description | MVX Code |
|---|
| PNEUMOVAX 23
| A-S Medication Solutions
| 50090-7036-00
| 50090-7036-01
| 33
| pneumococcal polysaccharide PPV23
| MSD
|
|---|
- NDC Pairs Retired
The following NDC pairs have been updated with Unit of Sale and Unit of Use end dates to reflect retirement.
| Sale Proprietary Name | Sale Labeler | Sale NDC11 | Use NDC11 | CVX Code | CVX Description | MVX Code |
|---|
| RabAvert
| GlaxoSmithKline Biologicals SA
| 58160-0964-12
| 58160-0966-01
| 176
| Rabies - IM fibroblast culture
| SKB
|
|---|
| RabAvert
| A-S Medication Solutions
| 50090-3096-00
| 58160-0966-01
| 176
| Rabies - IM fibroblast culture
| SKB
|
|---|
| FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE
| Sanofi Pasteur Inc.
| 49281-0355-15
| 49281-0355-78
| 202
| influenza, Southern Hemisphere, quadrivalent, with preservative
| PMC
|
|---|
| IPOL
| A-S Medication Solutions
| 50090-1693-09
| 50090-1693-00
| 10
| IPV
| PMC
|
|---|
- Other Updates to Existing NDC Records
The following NDC updates are reflected in the vaccine code set files.
| Change Description | Sale Proprietary Name | Sale Labeler | Sale NDC11 | Use NDC11 |
|---|
| Unit of Sale Route – corrected spelling of syringe
| HAVRIX
| A-S Medication Solutions
| 50090-1502-00
| 50090-1502-09
|
|---|
| Unit of Use updated UseUnitPackform field for consistency
| MENQUADFI
| A-S Medication Solutions
| 50090-6180-00
| 50090-6180-01
|
|---|
- Other NDC Updates not Included in the Published Code Fields
In addition to the code updates and retired NDCs cited above, several Unit of Use and Unit of Sale NDCs in the vaccine code set show dates of last update in January 2024. These are due to minor changes on the FDA files or internal fields updated by CDC that are not reflected in the files CDC publishes but do update the date of last update in CDC’s code set database.
These NDCs include:
| Sale Proprietary Name | Sale Labeler | Sale NDC11 | Use NDC11 |
|---|
| IPOL
| A-S Medication Solutions
| 50090-1693-09
| 50090-1693-00
|
|---|
| Comirnaty
| Pfizer Laboratories Div Pfizer Inc
| 00069-2025-10
| 00069-2025-01
|
|---|
| PREHEVBRIO
| VBI Vaccines (Delaware) Inc.
| 75052-0001-10
| 75052-0001-01
|
|---|
| PREVNAR 20
| A-S Medication Solutions
| 50090-6026-00
| 50090-6026-01
|
|---|
| Prevnar 20
| Wyeth Pharmaceutical Division of Wyeth Holdings LLC
| 00005-2000-10
| 00005-2000-01
|
|---|
| Prevnar 20
| Wyeth Pharmaceutical Division of Wyeth Holdings LLC
| 00005-2000-02
| 00005-2000-01
|
|---|
| TDVAX
| Grifols USA, LLC
| 13533-0131-01
| 13533-0131-00
|
|---|
| TDVAX
| MassBiologics
| 14362-0111-04
| 14362-0111-03
|
|---|
| TWINRIX
| GlaxoSmithKline Biologicals SA
| 58160-0815-52
| 58160-0815-43
|
|---|
| TWINRIX
| GlaxoSmithKline Biologicals SA
| 58160-0815-48
| 58160-0815-43
|
|---|
| Comirnaty
| Pfizer Laboratories Div Pfizer Inc
| 00069-2025-25
| 00069-2025-01
|
|---|
| PREVNAR 13
| Wyeth Pharmaceutical Division of Wyeth Holdings LLC
| 00005-1971-02
| 00005-1971-01
|
|---|
| PREVNAR 13
| Wyeth Pharmaceutical Division of Wyeth Holdings LLC
| 00005-1971-05
| 00005-1971-01
|
|---|
| PREVNAR 13
| Wyeth Pharmaceutical Division of Wyeth Holdings LLC, a subsidiary of Pfizer Inc.
| 00005-1971-04
| 00005-1971-01
|
|---|
